Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Statins
Statin response variability may be tied to hepatic transporter expression, polymorphisms
July 14th, 2006
Hepatic transporter expression and polymorphisms may be key determinants of intersubject variability in response to statin therapy. According to recent research from the United States, "The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, target liver HMG-CoA and are of proven benefit in the prevention of coronary heart disease. Rosuvastatin is an effective statin notable for liver selectivity and lack of significant metabolism." Vanderbilt University researchers R.H. Ho and colleagues explained, "We assessed the extent and relevance of hepatic transporters to rosuvastatin uptake. Transporters involved in rosuvastatin...
Source: Genomics & Genetics Weekly (2006-07-14)
|
